UnitedHealth stock sinks 4.7% after company confirms DOJ investigation into Medicare billing practices

UnitedHealth (UNH) shares dropped 4.7% after the company confirmed a Department of Justice investigation into its Medicare billing practices. The probe, reportedly stemming from Wall Street Journal disclosures, focuses on allegations that UNH and other insurers inflated patient diagnoses to secure excess payments from the federal Medicare Advantage program. This development adds to a series of legal and leadership controversies for the health insurance giant, whose stock has already seen a significant decline over the past year.

Analysis

UnitedHealth (UNH) shares declined 4.7% following the company's confirmation of a Department of Justice (DOJ) investigation into its Medicare billing practices. The probe, which stems from earlier Wall Street Journal reporting, scrutinizes allegations that the insurer improperly augmented patient diagnoses to receive excess payments from the Medicare Advantage program, a critical business segment. This regulatory action compounds an already precarious situation for the company, which has seen its stock fall approximately 50% over the last year amid a series of setbacks. These include a May 2024 insider trading lawsuit against senior executives related to a separate DOJ antitrust probe and significant public backlash over its claims denial practices, highlighted following the death of its CEO in December 2024. While UnitedHealth has asserted confidence in its practices and initiated its own third-party reviews, the confluence of legal, regulatory, and governance crises creates significant uncertainty regarding potential financial penalties and the future sustainability of its risk-assessment and billing models.

Key Decisions for Investors

• Investors should reassess their position in UNH given the material risk posed by the DOJ investigation into a core revenue stream, which could result in significant fines and mandated changes to its business practices.
• Closely monitor developments from the DOJ probe and the company's internal reviews, as any official charges, settlements, or changes in guidance will be a primary catalyst for the stock.
• The pattern of regulatory scrutiny, spanning both antitrust and Medicare fraud allegations, alongside the existing insider trading lawsuit, constitutes a major governance red flag that warrants significant caution for long-term holders.
• Given the extremely negative sentiment and high uncertainty, initiating new long positions is highly risky until there is greater clarity on the legal and financial ramifications of the investigation.